TABLE 3.
Top 10 contributors in terms of journal among the three datasets.
| PD1/PDL1 molecule | RCT of anti-PD1/PDL1 | Meta-analysis of anti-PD1/PDL1 | ||||||
|---|---|---|---|---|---|---|---|---|
| Source | IF | Records | Source | IF | Records | Source | IF | Records |
| ONCOIMMUNOLOGY | 5.869 | 445 | NEW ENGLAND JOURNAL OF MEDICINE | 74.699 | 28 | IMMUNOTHERAPY | 2.964 | 19 |
| CLINICAL CANCER RESEARCH | 10.107 | 396 | LANCET ONCOLOGY | 33.752 | 26 | MEDICINE | 1.552 | 17 |
| ONCOTARGET | - | 304 | LANCET | 60.392 | 13 | INTERNATIONAL IMMUNOPHARMACOLOGY | 3.943 | 13 |
| JOURNAL FOR IMMUNOTHERAPY OF CANCER | 9.913 | 296 | ANNALS OF ONCOLOGY | 18.274 | 11 | ONCOTARGET | - | 13 |
| CANCER IMMUNOLOGY RESEARCH | 8.728 | 284 | JOURNAL OF CLINICAL ONCOLOGY | 32.956 | 10 | ONCOTARGETS AND THERAPY | 3.337 | 12 |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.442 | 233 | JOURNAL OF THORACIC ONCOLOGY | 13.357 | 10 | FRONTIERS IN PHARMACOLOGY | 4.225 | 11 |
| CANCER RESEARCH | 9.727 | 209 | EUROPEAN JOURNAL OF CANCER | 7.275 | 9 | JAMA ONCOLOGY | 24.799 | 11 |
| PLOS ONE | 2.74 | 176 | FUTURE ONCOLOGY | 2.66 | 8 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 5.833 | 10 |
| SCIENTIFIC REPORTS | 3.998 | 171 | JAMA ONCOLOGY | 24.799 | 8 | ONCOIMMUNOLOGY | 5.869 | 10 |
| FRONTIERS IN IMMUNOLOGY | 5.085 | 164 | NATURE MEDICINE | 36.13 | 6 | CANCER MEDICINE | 3.491 | 9 |